Multiplex Assay Kit for Peroxisome Proliferator Activated Receptor Gamma (PPARg) ,etc. by FLIA (Flow Luminescence Immunoassay) 
PPAR-G; PPARG1; PPARG2; NR1C3; Glitazone Receptor; Nuclear Receptor Subfamily 1 Group C Member 3
(Note: Up to 8-plex in one testing reaction)
- UOM
- FOB US$ 472.00 US$ 490.00 US$ 517.00 US$ 553.00 US$ 590.00 US$ 644.00 US$ 726.00 US$ 907.00
- Quantity
Overview
Properties
- Product No.LMA886Bo
- Organism SpeciesBos taurus; Bovine (Cattle) Same name, Different species.
- ApplicationsFLIA Kit for Antigen Detection.
Research use only - DownloadInstruction Manual
- CategoryMetabolic pathwayEndocrinologyCardiovascular biologyDevelopmental scienceBone metabolism
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of recombinant Peroxisome Proliferator Activated Receptor Gamma (PPARg) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Peroxisome Proliferator Activated Receptor Gamma (PPARg) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 88-99 | 95 |
| EDTA plasma(n=5) | 81-96 | 90 |
| heparin plasma(n=5) | 82-103 | 92 |
| sodium citrate plasma(n=5) | 78-91 | 84 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Peroxisome Proliferator Activated Receptor Gamma (PPARg) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Peroxisome Proliferator Activated Receptor Gamma (PPARg) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Peroxisome Proliferator Activated Receptor Gamma (PPARg) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 81-93% | 80-90% | 91-101% | 79-104% |
| EDTA plasma(n=5) | 92-101% | 91-98% | 97-104% | 95-105% |
| heparin plasma(n=5) | 78-94% | 80-92% | 83-99% | 91-102% |
| sodium citrate plasma(n=5) | 91-99% | 85-92% | 82-98% | 91-103% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| 96-well plate | 1 | Plate sealer for 96 wells | 4 |
| Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
| Pre-Mixed Magnetic beads (22#:PPARg) | 1 | Analysis buffer | 1×20mL |
| Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
| Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
| Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
| Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
Test principle
Analyte-specific antibodies are pre-coated onto color-coded microparticles. Microparticles, standards, and samples are pipetted into wells and the immobilized antibodies bind the analytes of interest. After washing away any unbound substances, a biotinylated antibody cocktail specific to the analytes of interest is added to each well. Following a wash to remove any unbound biotinylated antibody, Streptavidin-Phycoerythrin conjugate (Streptavidin-PE), which binds to the biotinylated detection antibodies, is added to each well. A final wash removes unbound Streptavidin-PE and the microparticles are resuspended in buffer and read using the Luminex or Bio-Plex analyzer.The MFI developed is proportional to the concentration of analytes of interest in the sample.
Giveaways
Increment services
Citations
- Elevated levels of PPAR-gamma in the cerebrospinal fluid of patients with multiple sclerosisPubmed: 24021801
- Nonivamide enhances miRNA let‐7d expression and decreases adipogenesis PPARγ expression in 3T3‐L1 cellsPubmed:25704235
- Establishment of a rabbit model to study the influence of advanced glycation end products accumulation on osteoarthritis and the protective effect of pioglitazonePubMed: 26321377
- Evaluation of Protein Kinase Cβ and PPARγ Activity in Diabetic Rats Supplemented with Momordica charantiapmc:PMC4866090
- Evaluation of Protein Kinase Cβ and PPARγ Activity in Diabetic RatsSupplemented with Momordica charantia.pubmed:27190792
- Establishment of a rabbit model to study the influence of advanced glycation end productsaccumulation on osteoarthritis and the protective effect of pioglitazone.pubmed:26321377
- Unlike PPARgamma, neither other PPARs nor PGC-1alpha is elevated in the cerebrospinal fluid of patients with multiple sclerosispubmed:28483651
- Engulfment of Hb‐activated platelets differentiates monocytes into pro‐inflammatory macrophages in PNH patientsPubmed:29677388
- Simpson–Golabi–Behmel syndrome human adipocytes reveal a changing phenotype throughout differentiationPubmed:29574488
- Maternal omega-3 fatty acids and vitamin E improve placental angiogenesis in late-onset but not early-onset preeclampsiaPubmed: 31420792
- Hyperglycemia Changes Expression of Key Adipogenesis Markers (C/EBPα and PPARᵞ) and Morphology of Differentiating Human Visceral AdipocytesPubmed: 31398873
- Indomethacin and juglone inhibit inflammatory molecules to induce apoptosis in colon cancer cellsPubmed: 31916655
- In©\vitro effect of pine bark extract on melanin synthesis, tyrosinase activity, production of endothelin©\1 and PPAR in cultured melanocytes exposed to Ultraviolet?¡33960120
- TRPA1 Agonist Cinnamaldehyde Decreases Adipogenesis in 3T3-L1 Cells More Potently than the Non-agonist Structural Analog Cinnamyl Isobutyrate33403292
- Quantitative real-time measurement of endothelin-1-induced contraction in single non-activated hepatic stellate cells34343209
- Maternal Vitamin D Deficiency Reduces Docosahexaenoic Acid, Placental Growth Factor and Peroxisome Proliferator Activated Receptor Gamma levels in the Pup …34768025
- Melatonin attenuates cisplatin-induced acute kidney injury in mice: Involvement of PPARα and fatty acid oxidationPubmed:35367536